New Management of Cluster Headache Noboru Imai 1 1Department of Neurology, Japanese Red Cross Shizuoka Hospital Keyword: 群発頭痛 , CGRP , ガルカネズマブ , 翼口蓋神経節 , ニューロモデュレーション , cluster headache , calcitonin gene-related peptide , galcanezumab , sphenopalatine ganglion , neuromodulation pp.347-355
Published Date 2021/4/1
DOI https://doi.org/10.11477/mf.1416201766
  • Abstract
  • Look Inside
  • Reference


Galcanezumab, a CGRP monoclonal antibody drug, has been approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent cluster headaches. This was done after a randomized, double-blind, placebo-controlled trial found it to be effective and safe. Similarly sphenopalatine ganglion stimulation has been found to be effective and safe in a randomized, controlled trial as an acute treatment for chronic cluster headache. This article reviews the mechanisms of action of these therapies and their clinical trial results, clinical uses, and prospects in Japan.

Copyright © 2021, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院